Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small ...

Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...

Goldman Sachs-backed Septerna would be valued around $750 million. Drug developers have achieved resounding success in the ...

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule ...

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

Septerna, Inc SEPN IPO will take place October, 25 on the NASDAQ exchange under the ticker SEPN. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...

Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in ...